Med. praxi. 2022;19(1):35-38 | DOI: 10.36290/med.2022.005

Therapeutic approach to the treatment of arterial hypertension in an obese patient

MUDr. Peter Wohlfahrt, Ph.D.
Centrum kardiovaskulární prevence 1. LF UK a Fakultní Thomayerovy nemocnice, Praha
1. lékařská fakulta Univerzity Karlovy, Praha

Arterial hypertension (AH) and obesity are among the six most important risk factors leading to death in the world. Both risk factors increase the risk not only of cardiovascular disease, but also the risk of cancer and chronic kidney disease. There are close two-way links between obesity and AH. Obesity increases the risk of developing AH two to threefold and in obese patients, blood pressure control is more difficult to achieve. On the other hand, a positive family history of AH predicts development of central obesity. At the same time, people with higher blood pressure have a higher risk of weight gain than people with lower blood pressure. The central motif of blood pressure elevation in obesity is increased sodium and water retention due to renin-angiotensin system activation and increased sympathetic activity. Recent analysis of data from real practice points to efficiency and safety and metabolic neutrality of the fixed combination Perindopril/Indapamide in subjects with AH and obesity, type 2 diabetes mellitus or metabolic syndrome.

Keywords: arterial hypertension, obesity, renin-angiotensin system activation.

Published: February 23, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Wohlfahrt P. Therapeutic approach to the treatment of arterial hypertension in an obese patient. Med. praxi. 2022;19(1):35-38. doi: 10.36290/med.2022.005.
Download citation

References

  1. Murray CJL, Aravkin AY, Zheng P, et al. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020;396(10258):1223-1249. doi:10.1016/S0140-6736(20)30752-2. Go to original source... Go to PubMed...
  2. Higgins M, Kannel W, Garrison R, Pinsky J, Stokes J, 3rd. Hazards of obesity--the Framingham experience. Acta medica Scandinavica Supplementum. 1988;723:23-36. doi:10.1111/j.0954-6820.1987.tb05925.x. Go to original source... Go to PubMed...
  3. Krauss RM, Winston M, Fletcher BJ, Grundy SM. Obesity. 1998;98(14):1472-1476. doi:doi:10.1161/01.CIR.98. 14. 1472 Go to original source...
  4. Holecki M, Duława J, Chudek J. Resistant hypertension in visceral obesity. European Journal of Internal Medicine. 2012;23(7):643-648. doi:10.1016/j.ejim.2012. 04. 012. Go to original source...
  5. Allemann Y, Hutter D, Aeschbacher BC, Fuhrer J, Delacrétaz E, Weidmann P. Increased central body fat deposition precedes a significant rise in resting blood pressure in male offspring of essential hypertensive parents: a 5 year follow­‑up study. Journal of hypertension. Dec 2001;19(12):2143-2148. doi:10.1097/00004872-200112000-00005. Go to original source... Go to PubMed...
  6. Julius S, Valentini M, Palatini P. Overweight and hypertension: a 2-way street? Hypertension (Dallas, Tex: 1979). 2000;35(3):807-813. doi:10.1161/01.hyp.35. 3. 807. Go to original source...
  7. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. International journal of obesity (2005).2008;32(9):1431-1437. doi:10.1038/ijo.2008.102. Go to original source... Go to PubMed...
  8. http://www.euro.who.int/__data/assets/pdf_file/0005/ 53852/E91416.pdf.
  9. Marques A, Peralta M, Naia A, Loureiro N, de Matos MG. Prevalence of adult overweight and obesity in 20 European countries, 2014. European journal of public health. 2018;28(2):295-300. doi:10.1093/eurpub/ckx143. Go to original source... Go to PubMed...
  10. Cífková R, Bruthans J, Wohlfahrt P, et al. 30-year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post-MONICA, 1985-2016/17. PLoS One. 2020;15(5):e0232845. doi: 10.1371/journal.pone.0232845. Go to original source... Go to PubMed...
  11. da Silva AA, do Carmo JM, Li X, Wang Z, Mouton AJ, Hall JE. Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited. Can J Cardiol. 2020;36(5):671-682. doi:10.1016/j.cjca.2020. 02. 066. Go to original source...
  12. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity­‑induced hypertension: interaction of neurohumoral and renal mechanisms. Circulation research. 2015;116(6):991-1006. doi:10.1161/circresaha.116.305697. Go to original source... Go to PubMed...
  13. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity, kidney dysfunction and hypertension: mechanistic links. Nature reviews Nephrology. 2019;15(6):367-385. doi:10.1038/s41581-019-0145-4. Go to original source... Go to PubMed...
  14. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of Weight Reduction on Blood Pressure. 2003;42(5):878-884. doi:10.1161/01.HYP.0000094221.86888.AE. Go to original source... Go to PubMed...
  15. Okorodudu DO, Jumean MF, Montori VM, et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes (Lond). 2010 May;34(5):791-9. doi: 10.1038/ijo.2010.5. Epub 2010 Feb 2. PMID: 20125098. Go to original source... Go to PubMed...
  16. Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation.2012;126(10): 1301-1313. doi:10.1161/circulationaha.111.067264. Go to original source... Go to PubMed...
  17. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiological reviews. 2013;93(1): 359-404. doi:10.1152/physrev.00033.2011. Go to original source... Go to PubMed...
  18. Peters SAE, Bots SH, Woodward M. Sex Differences in the Association Between Measures of General and Central Adiposity and the Risk of Myocardial Infarction: Results From the UK Biobank. 2018;7(5):e008507. doi:10.1161/JAHA.117.008507. Go to original source... Go to PubMed...
  19. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & amp; Rehabilitation (EACPR). European Heart Journal. 2016;37(29):2315-2381. doi:10.1093/eurheartj/ehw106 %J European Heart Journal. Go to original source... Go to PubMed...
  20. Zhao Y, Zhang M, Luo X, et al. Association of 6-year waist circumference gain and incident hypertension. Heart. 2017;103(17):1347. doi:10.1136/heartjnl-2016-310760. Go to original source... Go to PubMed...
  21. Siebenhofer A, Jeitler K, Horvath K, et al. Long­‑term effects of weight­‑reducing drugs in people with hypertension. Cochrane Database Syst Rev. 2016;3:Cd007654. doi:10.1002/14651858.CD007654.pub4. Go to original source... Go to PubMed...
  22. Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med.2004;351(26):2683-2693. doi:10.1056/NEJMoa035622. Go to original source... Go to PubMed...
  23. Benaiges D, Climent E, Goday A, Flores­‑Le Roux JA, Pedro­‑Botet J. Bariatric surgery and hypertension: implications and perspectives after the GATEWAY randomized trial. Cardiovasc Diagn Ther. 2019;9(1):100-103. doi:10.21037/cdt. 2018. 10. 04. Go to original source...
  24. Jakobsen GS, Småstuen MC, Sandbu R, et al. Association of Bariatric Surgery vs Medical Obesity Treatment With Long­‑term Medical Complications and Obesity­‑Related Comorbidities. Jama. 2018;319(3):291-301. doi:10.1001/jama.2017.21055. Go to original source... Go to PubMed...
  25. Schiavon CA, Bersch­‑Ferreira AC, Santucci EV, et al. Effects of Bariatric Surgery in Obese Patients With Hypertension: The GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). Circulation. 2018;137(11): 1132-1142. doi:10.1161/circulationaha.117.032130. Go to original source... Go to PubMed...
  26. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 2018;39(33): 3021-3104. doi:10.1093/eurheartj/ehy339. Go to original source... Go to PubMed...
  27. Widimský J, Filipovský J, Ceral J, Cífková R, Linhart A, Monhart V, et al.. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2017. Doporučení České společnosti pro hypertenzi. Vnitr Lek. 2018;64(7-8):771-796.
  28. Farsang C, Dézsi CA, Brzozowska­‑Villatte R, De Champvallins M, Glezer M, Karpov Y. Beneficial Effects of a Perindopril/Indapamide Single­‑Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies. Adv Ther. 2021;38(4):1776-1790. doi:10.1007/s12325-021-01619-8. Go to original source... Go to PubMed...
  29. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Adrenergic Receptor Blockers and Weight Gain. Hypertension. 2001;37(2): 250-254. doi:doi:10.1161/01.HYP.37. 2. 250. Go to original source... Go to PubMed...
  30. Gammone MA, Efthymakis K, D'Orazio N. Effect of Third­‑Generation Beta Blockers on Weight Loss in a Population of Overweight­‑Obese Subjects in a Controlled Dietary Regimen. Journal of Nutrition and Metabolism. 2021:5767306. doi:10.1155/2021/5767306. Go to original source... Go to PubMed...
  31. Wohlfahrt P, Cífková R. Why rapid achievement of goal blood pressure is important in the treatment of arterial hypertension. Vnitrni lekarstvi. 2019;65(11):698-697. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.